This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
ARHGEF12 / Rho guanine nucleotide exchange factor 12 · IHC design guide
Design Immunohistochemistry for ARHGEF12
Plan ARHGEF12 paraffin-section IHC around mainly cytoplasmic staining and rare nuclear signal (HPA tissue IHC). This guide covers fixation, compartment-aware scoring, and the catalog antibody’s 2–5 μg/ml IHC range (datasheet A06802-3).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
ARHGEF12 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Mainly cytoplasmic; rare nuclear staining (HPA tissue IHC) | |
| Staining pattern | Cytoplasmic staining across cell types; rare nuclear signal (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A06802-3) | |
| Positive control | Adrenal gland+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections (standard IHC practice; not target-specific) | |
| Caveat | Staining and RNA have medium consistency (HPA tissue IHC) | |
| Regulation | Membrane recruitment on stimulation (UniProt) | |
| Isoform / epitope | 2 isoforms; no transmembrane segment; epitope coverage unknown (UniProt) |
Section 1
Recommended ARHGEF12 IHC & IF Protocols
Compare the catalog antibody’s IHC-P protocol (datasheet A06802-3) with two published ARHGEF12 IHC protocols (PMC12027205; PMC12374580).
| Sample | Paraffin-embedded human colorectal adenocarcinoma tissue; fixative not specified (datasheet A06802-3) |
| Fixation | Image fixative and duration unreported (datasheet A06802-3); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A06802-3); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A06802-3) |
| Primary antibody | Rabbit anti-ARHGEF12, 2-5 μg/ml (datasheet A06802-3) |
| Primary incubation | Overnight at 4 °C (datasheet A06802-3) |
| Detection | HRP-conjugated secondary, DAB chromogen (datasheet A06802-3) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | ARHGEF12-positive staining in glandular cells of adrenal gland (HPA tissue IHC: Medium). HPA tissue profile: Mainly cytoplasmic expression in several different cell types, including rare cases of nuclear expression. No signal in the no-primary control. |
💡Decision noteStart with EDTA pH 8.0 heat retrieval for the catalog antibody (datasheet A06802-3); use sodium citrate when reproducing that published method (PMC12027205 methods).
Section 2
What Is the Expected ARHGEF12 Staining Pattern?
ARHGEF12 is mainly cytoplasmic in tissue sections, with rare nuclear staining (HPA tissue IHC); membrane association is also plausible because it can move to the membrane upon stimulation and has no transmembrane segment (UniProt Q9NZN5). Expect staining in selected glandular, respiratory epithelial, and endothelial cells, with cell-dependent intensity (HPA tissue IHC). HPA rates the tissue staining “Approved,” with medium consistency against RNA expression (HPA tissue IHC).
| Cytoplasmic staining in adrenal or duodenal glandular cells, bronchial respiratory epithelium, or colonic endothelium. | This fits the reported medium staining in those cell populations (HPA tissue IHC). Judge the named cells within each section; the record does not predict uniform staining across every cell in that tissue (HPA tissue IHC). |
| Strong nuclear-only staining dominates the expected positive cells, with little cytoplasmic signal. | Treat this as a localization mismatch: tissue IHC is mainly cytoplasmic, though rare nuclear staining occurs (HPA tissue IHC). Plasma membrane and cytosol are the approved main ICC/IF locations; nucleoplasm is additional (HPA subcellular). |
| Prominent signal appears in adipocytes, marrow hematopoietic cells, or smooth muscle cells. | These cells are reported as not detected (HPA tissue IHC). Consider cross-reactivity or endogenous detection activity before assigning the signal to ARHGEF12 (general IHC practice); compare matched controls and cell morphology. |
| A uniform brown haze covers many cell types and empty tissue spaces. | That distribution is harder to reconcile with the reported cell-specific pattern (HPA tissue IHC). Background from detection reagents or insufficient blocking or washing is possible (general IHC practice); a reagent control helps distinguish it from cellular staining. |
| No signal appears in an adrenal glandular or bronchial epithelial positive control. | Both cell populations show medium staining in the supplied record (HPA tissue IHC). First check that the relevant cells are present and the detection run worked (general IHC practice); a single blank section does not prove biological absence. |
💡Expected ARHGEF12 appearanceCall a section positive when its expected cell population shows predominantly cytoplasmic, approximately medium chromogenic staining (HPA tissue IHC); widespread acellular haze or strong signal confined to reported negative cells warrants control review (HPA tissue IHC; general IHC practice).
| Compartment and activation | Cytoplasm and membrane are listed locations, and stimulation can move ARHGEF12 to the membrane (UniProt Q9NZN5). Tissue IHC is mainly cytoplasmic (HPA tissue IHC), so membrane accentuation can be assessed in context without requiring it in every section. |
| Cell-specific tissue pattern | Adrenal, appendix, duodenal, endometrial, epididymal, and fallopian tube glandular cells have medium staining; salivary glandular cells are not detected (HPA tissue IHC). Select and score controls by the named cell type. |
| Antibody evidence | The listed antibodies HPA018911 and CAB025581 are IHC “Approved” (HPA antibodies). Tissue staining has medium consistency with RNA data (HPA tissue IHC); approval supports use of the reported pattern but does not establish specificity in an untested specimen. |
| Isoforms and epitope uncertainty | UniProt lists 2 isoforms and reports isoform 2 in jejunum and testis (UniProt Q9NZN5). The supplied record gives no antibody epitope or isoform selectivity, so a tissue result cannot be assigned to either isoform from this evidence alone. |
| IF/ICC Q: What location should a separate IF guide expect? | A: Mainly plasma membrane and cytosol, with additional nucleoplasm (HPA subcellular). That approved ICC/IF localization complements tissue IHC's mainly cytoplasmic profile (HPA tissue IHC); it does not supply an IHC-P protocol. |
| Situation | Likely cause | Next action |
|---|---|---|
| Expected positive cells are unstained. | The sampled section may lack the named cells, or the staining run may have failed (general IHC practice); HPA reports medium signal in specified cells, not every cell (HPA tissue IHC). | Confirm cell identity on the counterstain, run a reported positive tissue alongside the sample, and check detection controls (HPA tissue IHC; general IHC practice). |
| Signal is mainly nuclear throughout the section. | Rare nuclear staining is reported, but a dominant nuclear-only pattern conflicts with the mainly cytoplasmic tissue profile (HPA tissue IHC). | Review morphology and a positive control, then compare staining with a second IHC-approved antibody if available (HPA antibodies; general IHC practice). |
| Reported negative cells stain strongly. | Cross-reactivity or endogenous detection activity may contribute (general IHC practice); the named cells are not detected in HPA tissue IHC. | Check a no-primary control and the detection system's endogenous-activity blocking steps; compare the same cell type in a reported negative tissue (general IHC practice; HPA tissue IHC). |
| Diffuse chromogen obscures cellular boundaries. | Nonspecific reagent binding, inadequate washing, or overdevelopment can raise background (general IHC practice). | Compare the no-primary control, review blocking and washes, and shorten chromogen development if the control also darkens (general IHC practice). |
| One glandular tissue is positive while another is blank. | Glandular staining differs by tissue: several named sites are medium, whereas salivary glandular cells are not detected (HPA tissue IHC). | Verify the tissue and cell labels before changing conditions; score each site against its own reported cell pattern (HPA tissue IHC). |
| Membrane-edge staining appears with cytoplasmic signal. | Membrane association is compatible with UniProt localization and stimulation-dependent translocation (UniProt Q9NZN5); tissue IHC remains mainly cytoplasmic (HPA tissue IHC). | Assess whether the signal follows intact cell borders and accompanies plausible cellular staining; use matched controls before interpreting isolated edge color (general IHC practice). |
Experiment evidence
IHC & IF images showing ARHGEF12 staining
A06802-3 · IHCIHC analysis of ARHGEF12L using anti-ARHGEF12L antibody (A06802-3). ARHGEF12L was detected in a paraffin-embedded section of human colorecta
A06802-3 · IHCIHC analysis of ARHGEF12L using anti-ARHGEF12L antibody (A06802-3). ARHGEF12L was detected in a paraffin-embedded section of human liver can
A06802-3 · IFIF analysis of ARHGEF12 using anti-ARHGEF12 antibody (A06802-3) and anti-Beta Tubulin antibody (M01857-3). ARHGEF12 was detected in immunocy
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000196914-ARHGEF12/tissue/cerebral+cortex#imid_5509952
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000196914-ARHGEF12/tissue/colon#imid_5509886
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000196914-ARHGEF12/tissue/liver#imid_5509887
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000196914-ARHGEF12/tissue/kidney#imid_5509880
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA018911; green = ARHGEF12, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA018911; green = ARHGEF12, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for ARHGEF12 IHC & IF
🧪Run colon first and score vessel-lining endothelial cells for Medium staining (HPA: Colon, endothelial cells, Medium). Run adipose tissue as the negative and score adipocytes (HPA: Adipose tissue, adipocytes, Not detected); on the colon slide, erythrocytes within vessel lumina should lack specific cellular staining (standard IHC practice).
Positive control tissue: Adrenal gland (Glandular cells, HPA Medium)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show ARHGEF12 in A-431, U-251MG, U2OS, with annotated localisation: Plasma membrane (approved), Cytosol (approved) (HPA subcellular).
Technical controls: Include a no-primary (secondary-only) control, a concentration-matched rabbit IgG control (catalog tissue-IHC caption: rabbit primary), and, if available, ARHGEF12 knockout tissue or a validated cognate-peptide block. For colon IHC, quench endogenous peroxidase and check vascular blood for DAB background (standard chromogenic IHC practice).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected A06802-3 paraffin-section caption does not state a fixative (catalog tissue-IHC caption: fixative unreported). That caption uses heat retrieval in EDTA at pH 8.0, but does not establish that retrieval is required (catalog tissue-IHC caption: EDTA retrieval). Frozen sections are not established as easier; ICC-IF images show plasma membrane and cytosolic localization (HPA: subcellular), while vascular blood may complicate DAB interpretation in colon (standard chromogenic IHC practice).
HPA tissue IHC evidence for ARHGEF12
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Glandular cells | Medium | Protein (IHC) | HPA → |
| Appendix | Glandular cells | Medium | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | Medium | Protein (IHC) | HPA → |
| Colon | Endothelial cells | Medium | Protein (IHC) | HPA → |
| Duodenum | Glandular cells | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Caudate | Glial cells | Not detected | Protein (IHC) | HPA → |
| Liver | Cholangiocytes | Not detected | Protein (IHC) | HPA → |
| Lymph node | Germinal center cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced ARHGEF12 IHC Tips
Troubleshoot ARHGEF12 staining in paraffin sections by checking retrieval, cellular localization, controls, and scoring against the available tissue evidence.
Which retrieval conditions should I try first for weak ARHGEF12 staining?
Start with heat-mediated retrieval in EDTA at pH 8.0 for paraffin sections (datasheet A06802-3). The selected tissue example used this retrieval before 2 μg/ml primary antibody overnight at 4°C; hold those conditions constant while assessing retrieval (caption A06802-3). If staining remains weak, vary heating duration across matched sections and compare cytoplasmic staining, tissue morphology, and nonspecific DAB deposition (standard IHC practice; HPA tissue IHC). Include a no-primary control and a reference section in each run so changes in detection or section quality do not appear to be retrieval effects (standard IHC practice).
Could fixation explain variable ARHGEF12 staining between paraffin sections?
The selected paraffin-section caption does not state a fixative, so ARHGEF12-specific fixation sensitivity is unknown (caption A06802-3). Record fixative identity, fixation duration, and processing interval for each specimen, then compare matched sections using the same retrieval and detection conditions (standard IHC practice). Keep heat retrieval in EDTA at pH 8.0 and the 2 μg/ml primary incubation overnight at 4°C during that comparison (caption A06802-3). Inspect morphology and a reference section from the same staining run before attributing signal differences to fixation; tissue staining patterns and protein modifications do not establish a fixation requirement (standard IHC practice; HPA tissue IHC; UniProt Q9NZN5).
Should ARHGEF12 staining appear cytoplasmic, membranous, or nuclear?
Score cytoplasmic staining and record any membrane-associated component: ARHGEF12 is reported in cytoplasm and membrane, with membrane translocation upon stimulation (UniProt Q9NZN5). Tissue IHC is mainly cytoplasmic with rare nuclear staining, while subcellular IF supports plasma membrane and cytosol localization plus an additional nucleoplasmic signal (HPA tissue IHC; HPA subcellular). ARHGEF12 has no transmembrane segment, so a membranous rim alone does not establish an extracellular epitope (UniProt Q9NZN5 topology). Compare compartments only in morphologically intact cells, and record experimental stimulation before interpreting a change in membrane-associated staining (standard IHC practice; UniProt Q9NZN5).
Can this antibody distinguish ARHGEF12 isoforms in tissue?
Do not assign isoform-specific IHC staining without an epitope map or isoform-specific validation for the catalog antibody (standard IHC interpretation). UniProt lists 2 isoforms and reports isoform 2 in jejunum and testis, but tissue distribution alone cannot identify which isoform generated a stain (UniProt Q9NZN5). The protein contains PDZ 72–151, RGSL 367–558, DH 787–977, and PH 1019–1132 domains; their positions do not identify the antibody epitope (UniProt Q9NZN5). If isoform attribution matters, obtain epitope information and compare appropriate isoform-specific controls before interpreting compartment or intensity differences (standard IHC practice).
How can IF help check an ambiguous chromogenic ARHGEF12 pattern?
Use IF as a complementary localization check while retaining the paraffin-section IHC conditions for the chromogenic result (standard IHC/IF practice; caption A06802-3). In multiplex IF, pair ARHGEF12 with a marker for the expected cell type, such as an endothelial marker when assessing colon endothelium, and inspect both cell identity and compartment (HPA tissue IHC; standard IF practice). Choose spectrally separated fluorophores and favor a longer-wavelength channel where tissue autofluorescence obscures shorter-wavelength signal (standard IF practice). For a cytosolic epitope, permeabilize appropriately; membrane association alone does not establish extracellular accessibility, and the antibody epitope is unspecified (UniProt Q9NZN5 topology; standard IF practice).
How do I reduce diffuse DAB background without losing ARHGEF12 signal?
Compare the stained section with a no-primary control to separate antibody-dependent staining from background generated by the detection workflow (standard IHC practice). The selected tissue example used 10% goat serum blocking, a 2 μg/ml primary incubation overnight at 4°C, and peroxidase-based DAB detection (caption A06802-3). For excess background, check the peroxidase block, washing, secondary-antibody conditions, and DAB development on matched sections before lowering primary concentration (standard IHC practice). Preserve a morphologically intact reference section and assess cell-localized cytoplasmic staining, since diffuse staining alone does not match the main tissue pattern (standard IHC practice; HPA tissue IHC).
How should I quantify ARHGEF12 IHC across heterogeneous tissue? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and compartment before scoring, because tissue IHC is mainly cytoplasmic and expression varies among cell types (HPA tissue IHC). Within each annotated region, report the percentage of positive cells and an intensity-weighted H-score, or count positive cells per mm² when cell density is the main question (standard IHC practice). Normalize scores to the number of evaluable cells or viable tissue area, and apply the same threshold, counterstain, and DAB development criteria across sections (standard IHC practice). Record cytoplasmic, membranous, and nuclear signals separately so a compartment shift does not masquerade as a change in overall abundance (UniProt Q9NZN5; HPA tissue IHC; standard IHC practice).
What findings distinguish credible ARHGEF12 staining from artefact?
A credible result shows cell-associated staining with a predominantly cytoplasmic pattern and a possible membrane-associated component (HPA tissue IHC; UniProt Q9NZN5). Check the stained cells against the annotated tissue: HPA reports medium endothelial staining in colon, while its overall tissue IHC profile has only medium consistency with RNA expression (HPA tissue IHC). Treat isolated strong nuclear staining cautiously because nuclear cases are rare in tissue IHC, although nucleoplasmic localization is additionally reported by IF (HPA tissue IHC; HPA subcellular). Exclude section edges, necrotic regions, and signal persisting in no-primary controls before calling a positive result; endogenous peroxidase can contribute to chromogenic background (standard IHC practice).
Boster reagents
Best ARHGEF12 / Rho guanine nucleotide exchange factor 12 IHC Antibodies
A06802-3 has IHC images from human paraffin-embedded tumors and an IF image from A549 cells (catalog image captions); listed reactivity includes human, mouse, and rat (catalog reactivity).
Real IHC data
Anti-LARG/ARHGEF12 Antibody ®
Cat # A06802-3
The sole card, A06802-3, lists IHC, IF, and ICC applications (catalog applications) and shows staining in paraffin sections of human colorectal adenocarcinoma, liver cancer, parotid acinar cell carcinoma, and cervical squamous cell carcinoma (catalog IHC captions). Its IF image shows A549 cells (catalog IF caption).
Which to pick: For tissue IHC, choose A06802-3: its own paraffin-section caption documents EDTA retrieval at pH 8.0 and 2 μg/ml primary antibody (catalog IHC caption); the fixative is unreported (catalog IHC caption). For IF/ICC, the same rabbit-host SKU lists both applications (catalog host and applications), and its A549 IF image uses 5 μg/ml (catalog IF caption). For cross-species planning, A06802-3 lists human, mouse, and rat reactivity (catalog reactivity).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q9NZN5 (ARHGC_HUMAN, Rho guanine nucleotide exchange factor 12).
- Human Protein Atlas. ARHGEF12 tissue IHC expression (reliability: Approved).
- Human Protein Atlas. ARHGEF12 subcellular location (ICC-IF): Mainly localized to the plasma membrane and cytosol. In addition localized to the nucleoplasm..
- Human Protein Atlas. ARHGEF12 antibody validation summary (2 antibodies).
- METTL3 Promotes Cutaneous T-Cell Lymphoma Progression by Regulating ARHGEF12 Expression. International journal of molecular sciences 2025 — PMC12027205.
- Comprehensive exome profiling identifies ARHGEF12 mutation as a driver in gastric cancer with ovarian metastasis. Theranostics 2025 — PMC12374580.
- Identification of Arhgef12 and Prkci as genetic modifiers of retinal dysplasia in the Crb1rd8 mouse model. PLoS genetics 2022 — PMC9212170.
- Trans-Synaptic Signaling through the Glutamate Receptor Delta-1 Mediates Inhibitory Synapse Formation in Cortical Pyramidal Neurons. Neuron 2019 — PMC6926483.
- PubMed PMID:10681437 — UniProt-cited evidence.
- PubMed PMID:15489334 — UniProt-cited evidence.
- PubMed PMID:9205841 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for ARHGEF12 (Rho guanine nucleotide exchange factor 12). Expected localisation Mainly cytoplasmic; rare nuclear staining (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A06802-3). Validated IHC antibody: A06802-3 at 2-5 μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Adrenal gland (Glandular cells); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human colorectal adenocarcinoma tissue; fixative not specified (datasheet A06802-3); 2. Fixation: Image fixative and duration unreported (datasheet A06802-3); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A06802-3); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A06802-3); 8. Primary antibody: Rabbit anti-ARHGEF12, 2-5 μg/ml (datasheet A06802-3); 9. Primary incubation: Overnight at 4 °C (datasheet A06802-3). Watch for: Fixation: Keep fixation consistent across sections (standard IHC practice; not target-specific); Caveat: Staining and RNA have medium consistency (HPA tissue IHC); Isoform / epitope: 2 isoforms; no transmembrane segment; epitope coverage unknown (UniProt); Regulation: Membrane recruitment on stimulation (UniProt). Evidence: UniProt Q9NZN5, HPA tissue IHC · Approved, HPA ICC-IF · Mainly localized to the plasma membrane and cytosol. In addition…, Datasheet A06802-3, PMC12027205, PMC12374580. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/ARHGEF12/immunohistochemistry-ihc-guide.